Header Logo

Connection

WILLIAM PEACOCK to Stroke

Back to Details
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Stroke.
WILLIAM PEACOCK
Connection Strength
2.284
Stroke
  1. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2017 Mar 01; 119(5):753-759.
    View in: PubMed
    Score: 0.309
  2. CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Ann Emerg Med. 2017 May; 69(5):541-550.e1.
    View in: PubMed
    Score: 0.309
  3. Where Are the Stroke Markers? Clin Chem. 2017 01; 63(1):252-254.
    View in: PubMed
    Score: 0.305
  4. Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation. J Am Coll Cardiol. 2016 09 06; 68(10):1144-6.
    View in: PubMed
    Score: 0.304
  5. Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies. Am J Med. 2016 Nov; 129(11S):S41-S46.
    View in: PubMed
    Score: 0.303
  6. Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. Vasc Health Risk Manag. 2009; 5:783-91.
    View in: PubMed
    Score: 0.187
  7. High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke. 2020 08; 51(8):2386-2394.
    View in: PubMed
    Score: 0.099
  8. Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. Stroke. 2020 07; 51(7):2139-2147.
    View in: PubMed
    Score: 0.099
  9. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 07; 378(23):2191-2201.
    View in: PubMed
    Score: 0.085
  10. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. J Stroke Cerebrovasc Dis. 2018 Jun; 27(6):1673-1682.
    View in: PubMed
    Score: 0.084
  11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017 08; 48(8):2142-2149.
    View in: PubMed
    Score: 0.080
  12. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Heart Lung Circ. 2018 Mar; 27(3):390-393.
    View in: PubMed
    Score: 0.079
  13. Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. Curr Med Res Opin. 2016 06; 32(6):1117-20.
    View in: PubMed
    Score: 0.018
  14. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
    View in: PubMed
    Score: 0.012
  15. Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2006 Jun 15; 97(12):1707-12.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.